Benefits
Resveratrol delivery — primary practical application
Polygonum cuspidatum is the commercial source for ~95% of resveratrol supplements globally — far more economical than extracting from grape skins. The benefits attributed to 'Japanese knotweed' largely overlap with those of trans-resveratrol itself (cardiovascular, anti-inflammatory, antioxidant, longevity research) — see Resveratrol entry for primary evidence. Knotweed extracts at 8% trans-resveratrol are essentially resveratrol delivery vehicles, and the amount delivered is small: even at the top of the label range, 500 mg twice a day, that is about 80 mg of resveratrol per day, while the resveratrol blood-pressure meta-analysis found an effect only in trials using 150 mg/day or more.
Lower inflammatory markers in two small trials of the extract (blood markers only)
Two small placebo-controlled trials used the plant extract rather than purified resveratrol, both at 200 mg/day of the same commercial extract standardized to 20% trans-resveratrol (40 mg trans-resveratrol) for 6 weeks. In male professional basketball players, 24 recruited and 20 completing, plasma TNF-α and IL-6 fell in the extract group and differed significantly from placebo (Zahedi 2013). In 20 healthy normal-weight adults, the same daily dose lowered mononuclear-cell reactive oxygen species and plasma TNF-α, IL-6 and C-reactive protein (Ghanim 2010). Both trials measured blood markers only: no symptom, recovery, illness or performance outcome was measured, and 10 people per group settles nothing.
Lipid effects in animals only: no human lipid trial of knotweed
Polydatin (resveratrol's glycoside form, more abundant in knotweed than the aglycone) lowered total cholesterol, triglycerides and LDL in cholesterol-fed rabbits given 25 to 100 mg/kg/day and in high-fat-fed hamsters. The two animal papers disagree on the ratios that matter most: the rabbit study reported a fall in the TC/HDL-C ratio, the hamster study a rise in both the LDL-C/HDL-C and TC/HDL-C ratios. These are animal doses many times a human serving, and no trial has measured blood lipids in people taking knotweed. The borrowed human evidence does not close the gap: the resveratrol blood-pressure meta-analysis was null overall and moved systolic pressure only in trials using 150 mg/day or more, which this extract does not supply.
No human longevity data: sirtuin and mitochondrial claims come from resveratrol mechanism work
All sirtuin-1 activation, mitochondrial biogenesis, and longevity claims associated with knotweed supplements derive from resveratrol evidence — not knotweed-specific trials. The unique compounds in knotweed (emodin, polydatin) have additional mechanistic interest but limited human longevity data of their own.
Mechanism of action
Resveratrol delivery → SIRT1 activation, AMPK, NAD+ pathways
Trans-resveratrol activates sirtuin-1 (SIRT1), enhances AMPK signaling, and supports NAD+ pool maintenance — molecular mechanisms underlying caloric restriction mimetic effects. ALL of these mechanisms apply equally to resveratrol from any source (knotweed, grape, blueberry); knotweed's role is purely as economic source. See Resveratrol entry for detailed mechanism discussion.
Polydatin pharmacokinetic advantage
Polydatin (resveratrol-3-O-β-D-glucoside) is hydrolyzed to free resveratrol by gut microbiota. Some research suggests polydatin may have higher oral bioavailability than free resveratrol due to delayed hydrolysis providing more sustained absorption. Knotweed's high polydatin content (often equal to or exceeding free resveratrol) may offer this kinetic advantage.
Emodin antimicrobial and cathartic
Emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) provides antimicrobial activity against bacteria, fungi, and viruses in vitro. Also has stimulant laxative effect (similar mechanism to senna anthraquinones) — relevant to dose-related GI side effects of knotweed. Distinguishes raw knotweed from purified resveratrol.
Laboratory activity against Borrelia bacteria in a dish, with no human evidence
In a Johns Hopkins laboratory screen of 15 natural products, 12 of them botanical, Polygonum cuspidatum extract was one of the two most active against both growing and stationary-phase Borrelia burgdorferi in culture, inhibiting growth at extract concentrations of 0.25 to 0.5 percent, but unlike Cryptolepis sanguinolenta it did not eradicate the bacteria on subculture. That is a test-tube result. No study has shown that swallowing the extract produces those concentrations in human tissue, and no trial has tested it in anyone with Lyme disease. Lyme disease and babesiosis are treated with prescription antibiotics; anyone with a tick-borne infection, or persistent symptoms after treatment, needs a physician rather than a supplement.
Clinical trials
Randomized controlled trial (Zahedi HS, Jazayeri S, Ghiasvand R, Djalali M, Eshraghian MR 2013, Int J Prev Med 4(Suppl 1):S1-S4).
Male professional basketball players aged 17 to 35 randomized to Polygonum cuspidatum extract or placebo for 6 weeks: 24 were recruited and 20 completed, 10 per group. The dose was 200 mg/day of a commercial extract (Pure Encapsulations) standardized to 20% trans-resveratrol, equal to 40 mg trans-resveratrol. Funded by Tehran University of Medical Sciences, no conflict of interest declared.
Plasma TNF-α and IL-6 fell in the extract group and did not change in the placebo group, and the two groups differed significantly after 6 weeks. Only blood markers were measured: no training adaptation, soreness, injury or performance outcome was recorded, and the authors did not measure resveratrol blood levels. With 10 people per group this is preliminary. It is one of three placebo-controlled human studies that used this commercial knotweed extract.
Two in vitro screens: Feng J, Leone J, Schweig S, Zhang Y 2020, Front Med (Lausanne) 7:6 (Borrelia burgdorferi); and Zhang Y, Alvarez-Manzo H, Leone J, Schweig S, Zhang Y 2021, Front Cell Infect Microbiol 11:624745 (Babesia duncani in hamster red blood cells). Neither study involved human participants.
No people. Laboratory cultures only: Borrelia burgdorferi in broth culture, and Babesia duncani growing in hamster red blood cells, exposed to Polygonum cuspidatum extract alongside 14 other natural products in the Borrelia screen and a further panel of herbal medicines in the Babesia screen.
Polygonum cuspidatum was one of the two most active of the 15 natural products tested against both growing and stationary-phase Borrelia (inhibitory at 0.25 to 0.5 percent extract), but it did not eradicate the bacteria on subculture, and it was one of five extracts that inhibited Babesia duncani in culture. Adding an extract to a dish is not the same as swallowing it: no study has shown that oral doses reach these concentrations in human tissue, and no trial has tested knotweed in anyone with Lyme disease or babesiosis. Both are serious infections treated with prescription antibiotics.
Animal studies (Xing WW, Wu JZ, Jia M, Du J, Zhang H, Qin LP 2009, Biomed Pharmacother 63(7):457-462; Du J, Sun LN, Xing WW, Huang BK, Jia M, Wu JZ, Zhang H, Qin LP 2009, Phytomedicine 16(6-7):652-658).
Animals, not people: 32 male rabbits fed a high fat and cholesterol diet, with 8 more on a normal diet as controls, given oral polydatin at 25, 50 or 100 mg/kg/day for 3 weeks; and high fat and cholesterol fed hamsters given polydatin.
Polydatin lowered total cholesterol, triglycerides and LDL cholesterol in both species. The ratios went in opposite directions: the rabbit paper reports the TC/HDL-C ratio fell, the hamster paper reports polydatin raised both the LDL-C/HDL-C and TC/HDL-C ratios. The rabbit doses, 25 to 100 mg/kg/day, are many times what a human supplement supplies, and no trial has measured blood lipids in people taking knotweed or polydatin.